Michelle Nuno, PhD

Assistant Professor of Clinical Population and Public Health Sciences

Image of Michelle Nuno, PhD
Is this your profile? Click to edit

Overview

I am an Assistant Professor of Clinical Population and Public Health Sciences in the Division of Biostatistics at the University of Southern California. I received a B.S. in Applied Mathematics from the University of California, Riverside in 2015. I then went on to complete my graduate work at the University of California, Irvine, where I received an M.S in Statistics in 2017 and a Ph.D. in Statistics in 2020. My research interests include clinical trials and the development of robust statistical methodology for efficient sampling designs. I am particularly interested in biomedical applications in Alzheimer’s disease and pediatric oncology.

Awards

  • University of California, Irvine: Carl Cotman Young Investigator Award (UCI MIND), 2020
  • University of California, Irvine: Information and Computer Science Latino Excellence Award, 2019
  • University of California, Irvine: National Science Foundation Graduate Research Fellowship Program, 2017
     – 2020
  • University of California, Irvine: Achievement Rewards for College Scientists Scholar, 2017
     – 2019
  • University of California, Irvine: Robert L. Newcomb Memorial Endowed Graduate Student Award- UCI Statistics, 2016
  • University of California, Irvine: Eugene Cota Robles Fellowship, 2015
     – 2020
  • University of California, Irvine: Provost Ph.D. Fellow, 2015

Education and Training

  • University of California, Riverside, Riverside, CA — B.S. — 06/2015 — Applied Mathematics
  • University of California, Irvine, Irvine, CA — M.S. — 06/2017 — Statistics
  • University of California, Irvine, Irvine, CA — Ph.D. — 06/2020 — Statistics

Research Keywords

  • Survival analysis
  • Efficient sampling designs
  • Model misspecification
  • pediatric oncology
  • Alzheimer's disease

Publications

  • Second Malignancies in Children and Adolescents With Extracranial Germ Cell Tumors: A Report From the Malignant Germ Cell Tumor International Consortium. Pediatr Blood Cancer. 2026 May; 73(5):e70206.. View in PubMed
  • Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices. Cancer. 2025 Oct 15; 131.. View in PubMed
  • Vaginal germ cell tumors: results from the international retrospective VAGIPED study. Br J Cancer. 2025 Dec; 133(11):1668-1674.. View in PubMed
  • Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. J Natl Cancer Inst. 2025 Sep 01; 117(9):1764-1773.. View in PubMed
  • Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia. JNCI Cancer Spectr. 2025 Apr 30; 9(3).. View in PubMed
  • Standard-Dose Versus High-Dose Cisplatin for Intermediate/Poor-Risk Extracranial Malignant Germ Cell Tumors: Re-Analysis of Pediatric Oncology Group 9049 and Children’s Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification. Pediatr Blood Cancer. 2025 Jun; 72(6):e31665.. View in PubMed
  • On the use of external controls in clinical trials. J Natl Cancer Inst Monogr. 2025 03 01; 2025(68):30-34.. View in PubMed
  • Impacts of informant replacement in two industry-sponsored Alzheimer’s disease clinical trials. Alzheimers Dement (N Y). 2024 Oct-Dec; 10(4):e70009.. View in PubMed
  • Bayesian Response Adaptive Randomization for Randomized Clinical Trials With Continuous Outcomes: The Role of Covariate Adjustment. Pharm Stat. 2025 Mar-Apr; 24(2):e2443.. View in PubMed
  • Clinical practice guideline-inconsistent chemotherapy-induced vomiting prophylaxis in pediatric cancer patients in community settings: A Children’s Oncology Group study. Pediatr Blood Cancer. 2024 11; 71(11):e31295.. View in PubMed